Zai Lab Ltd is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for various diseases. The company was founded in 2014 by Dr. Samantha Du, a seasoned biotech executive with extensive experience in the pharmaceutical industry. Zai Lab is headquartered in Shanghai, China, and has rapidly become a prominent player in the biopharmaceutical sector, particularly in the field of oncology and immunology.
Zai Lab is dedicated to advancing the discovery, development, and commercialization of transformative medicines to address unmet medical needs in China and beyond. The company's pipeline includes a wide range of novel therapies, spanning different therapeutic areas such as oncology, infectious diseases, autoimmune disorders, and more. They collaborate with global pharmaceutical companies and leverage their expertise to accelerate the development of innovative drugs.
Zai Lab's achievements include receiving approvals and launching several innovative drugs in China, expanding its pipeline through in-licensing agreements and collaborations with leading global biopharmaceutical companies, and securing partnerships for the development and commercialization of potential breakthrough treatments.
As a testament to its commitment to scientific excellence and innovation, Zai Lab has built a strong team of researchers, clinicians, and executives who work together to bring life-changing medicines to patients in China and beyond. Through its dedication to advancing healthcare solutions, Zai Lab continues to make significant strides in the biopharmaceutical industry and improve patient outcomes.